PRRSV recombinant antigen A1 inhibits the expression of CD163 on the cell surface by inducing the polarization of M1 macrophage subset, which can further effectively reduce virus invasionreduce infection. A1 can regulate the endogenous genes of alveolar macrophages to activate Th1-type immune responseenhance cellular immunity. Therefore, this technical invention will be beneficial to screen the new generation of PSSRV candidate structural vaccines.

This technology produced the PRRSV A1 antigen, which can up-regulate the polarization of the alveolar macrophage. The A1 antigen containing the full-length ORF5, partial ORF6specific T cell epitope. The constructed PRRSV A1 can effectively reduce the expression of CD163reduce M2 polarizationfurther can stimulate the activation of Th1 cells. This innovative technology can provide the development of PRRSV recombinant antigen as the new generation of candidate structure vaccines.

"The technical characteristics are as follows:
1. Using the baculovirus expression system, the recombinant structural antigen A1 has a post-translational modificationtherefore A1 antigen is more similar to the prototype virus protein structure.
2. It has the dual effects of inducing innateadaptive immunity.
3. It can regulate the polarization of porcine alveolar macrophagesreduce the ability of the virus to engage with host cells.
  This innovative technology can provide the develop of a new generation of PRRSV antigen as candidate structure vaccine."

天使投資人、策略合作夥伴